Epilepsy

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
6 Unique sponsors
4 Unique IMPs
4 Commercial trials
Drug classes (ATC)
ATC code not specified 4
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 1 Phase II: 2 Phase I (Other): 3

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial

Phase II

2 trials
  • Eisai Limited Commercial
    PERAMPANEL
    2023-507794-17-00 4 countries 2019 n=54
    Recruiting
  • Azienda Ospedaliera Universitaria Meyer IRCCS Academic
    CANNABIDIOL
    2023-503709-12-00 1 country 2024 n=30 Orphan
    Recruiting

Phase I (Other)

3 trials
  • Quralis Corp. Commercial
    IMP not specified
    2025-524310-28-00 1 country 2026 n=48
    Recruiting
  • Rapport Therapeutics Inc. Commercial
    IMP not specified
    2024-512151-21-00 1 country 2024 n=24
    Ended
  • Trevena Inc. Academic
    TRV045
    2022-502638-17-00 1 country 2023 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Quralis Corp. Commercial 1 Phase I (Other) 1
Rapport Therapeutics Inc. Commercial 1 Phase I (Other) 0
Eisai Limited Commercial 1 Phase II 1
UCB Biopharma Commercial 1 Phase III 0
Trevena Inc. Academic 1 Phase I (Other) 0
Azienda Ospedaliera Universitaria Meyer IRCCS Academic 1 Phase II 1
New trials by year
2019
1
2020
1
2023
1
2024
2
2026
1
← All indication landscapes